Multiomics Analysis of Interleukin-21 as a Potential Immunologic and Biomarker in Hepatocellular Carcinoma

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Interleukin-21 (IL-21) is a cytokine known for its antitumor properties, enhancing CD8+ T cell responses.
• IL-21 has shown efficacy in improving immune checkpoint inhibitor (ICI) treatment outcomes in several solid tumors.
• The specific role of IL-21 in hepatocellular carcinoma (HCC) and its impact on ICI therapy remains unclear.

Purpose of the Study:

• To investigate the antitumor effects of IL-21 in HCC.
• To determine the influence of IL-21 on the efficacy of ICI treatment in HCC patients.

Main Methods:

• Transcriptome sequencing analysis was employed to assess gene expression profiles.
• Immunohistochemistry was used for validation of key findings.
• Correlation between IL-21 expression, immune cell infiltration, and clinical outcomes was analyzed.

Main Results:

• Higher IL-21 expression was associated with a better prognosis in HCC patients.
• HCC tumors with high IL-21 expression exhibited increased infiltration of CD8+ T cells.
• Elevated IL-21 levels correlated with increased expression of immune checkpoints and enhanced response to ICI treatment.

Conclusions:

• IL-21 demonstrates significant antitumor effects in HCC.
• IL-21 enhances ICI treatment efficacy by promoting CD8+ T cell infiltration and immune checkpoint gene expression.
• IL-21 represents a potential therapeutic target for improving HCC patient outcomes.